How GLP-1 changed metabolic research

Brand names made GLP-1 famous. The biology is older — and more interesting — than the memes. Glucagon-like peptide-1 is released from the gut after a meal, tightens insulin in a glucose-dependent way, slows gastric emptying, and talks to satiety circuits. Drucker and Nauck mapped that incretin system in 2006. Large outcome trials arrived later. The culture caught up in 2021.

What STEP 1 actually measured

Wilding and colleagues randomized 1,961 adults with overweight or obesity, without diabetes, to once-weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention, for 68 weeks. Mean body weight moved −14.9% on drug versus −2.4% on placebo. 50.5% of the semaglutide group lost at least 15% of baseline weight, against 4.9% on placebo. Gastrointestinal events were the common reason people stopped. That is a large, randomized, labeled-product trial — and one of the most frequently referenced screenshots in adjacent marketing.

A 14.9% mean is a trial result on a named drug product — precise, powerful, and tied to that product’s program.

Inspired Labs ILGLP-1 is a research analog in the GLP-1 conversation. It is not semaglutide. It is not Wegovy. It does not carry the pen, the titration schedule, the indication, or the manufacturing process behind STEP 1. The laboratory questions that remain interesting are still close to the originals: receptor engagement, incretin signaling, and how a modified peptide behaves in a defined assay.